Clinical Utility and Cost Savings in Predicting Inadequate Response to Anti-TNF Therapies in Rheumatoid Arthritis

Clinical Utility and Cost Savings in Predicting Inadequate Response to Anti-TNF Therapies in Rheumatoid Arthritis

Abstract Introduction The PrismRA® test identifies rheumatoid arthritis (RA) patients who are unlikely to respond to anti-tumor necrosis factor (anti-TNF) therapies. This study evaluated the clinical and financial outcomes of incorporating PrismRA into routine clinical care of RA patients. Methods A...

Full description

Bibliographic Details
Main Authors: Martin J. Bergman, Alan J. Kivitz, Dimitrios A. Pappas, Joel M. Kremer, Lixia Zhang, Anna Jeter, Johanna B. Withers
Format: Article
Language:English
Published: Adis, Springer Healthcare 2020-08-01
Series:Rheumatology and Therapy
Subjects:
Anti-TNF therapies
Budget impact
Clinical utility
Precision medicine
Rheumatoid arthritis
Online Access:https://doi.org/10.1007/s40744-020-00226-3

Internet

https://doi.org/10.1007/s40744-020-00226-3

Similar Items